USP5 deubiquitinates and stabilizes IMPDH2, to promote hepatocellular carcinoma progression

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Oncogene

• Publication date

  2025-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41388-025-03355-7PMID 40164869
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PFKP deubiquitination and stabilization by USP5 activate aerobic glycolysis to promote triple-negative breast cancer progression

  2024cited by this paper
• USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition

  2024cited by this paper
• Lower ratio of IMPDH1 to IMPDH2 sensitizes gliomas to chemotherapy

  2024cited by this paper
• The deubiquitinase USP5 promotes cholangiocarcinoma progression by stabilizing YBX1.

  2024cited by this paper
• E2F1-regulated USP5 contributes to the tumorigenic capacity of glioma stem cells through the maintenance of OCT4 stability.

  2024cited by this paper
• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer

  2024cited by this paper
• USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein

  2024cited by this paper
• Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1

  2024cited by this paper
• c‐Myc–IMPDH1/2 axis promotes tumourigenesis by regulating GTP metabolic reprogramming

  2023cited by this paper
• Deubiquitinases in cancer

  2023cited by this paper
• Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway.

  2023cited by this paper
• Super enhancer-regulated lncRNA LINC01089 induces alternative splicing of DIAPH3 to drive hepatocellular carcinoma metastasis.

  2023cited by this paper
• Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway

  2023cited by this paper
• The ubiquitin‐specific protease 5 mediated deubiquitination of LSH links metabolic regulation of ferroptosis to hepatocellular carcinoma progression

  2023cited by this paper
• ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy

  2023cited by this paper
• USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway

  2023cited by this paper
• METTL5 stabilizes c‐Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression

  2023cited by this paper
• CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells

  2022cited by this paper
• USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity

  2022cited by this paper
• IMPDH inhibition activates TLR‐VCAM1 pathway and suppresses the development of MLL‐fusion leukemia

  2022cited by this paper
• USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer

  2022cited by this paper
• Hepatocellular carcinoma

  2022cited by this paper
• USP5 promotes breast cancer cell proliferation and metastasis by stabilizing HIF2α

  2022cited by this paper
• Macrophage‐derived extracellular vesicles regulates USP5‐mediated HDAC2/NRF2 axis to ameliorate inflammatory pain

  2021cited by this paper
• A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma

  2021cited by this paper
• Circular RNA circPFKP promotes cell proliferation by activating IMPDH2 in prostate cancer.

  2021cited by this paper
• USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1

  2021cited by this paper
• Anti-rods/rings autoantibody and IMPDH filaments: an update after fifteen years of discovery.

  2020cited by this paper
• Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.

  2020cited by this paper
• USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma

  2019cited by this paper
• Structure and function of USP5: Insight into physiological and pathophysiological roles.

  2019cited by this paper
• IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma

  2019cited by this paper
• Ubiquitin specific peptidase 5 regulates colorectal cancer cell growth by stabilizing Tu translation elongation factor

  2019cited by this paper
• Hepatocellular carcinoma

  2018cited by this paper
• IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways

  2018cited by this paper
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

  2018influential reference
• Deubiquitylating enzymes and drug discovery: emerging opportunities

  2017cited by this paper
• Smurf1 represses TNF-α production through ubiquitination and destabilization of USP5.

  2016cited by this paper
• Deubiquitylases from genes to organism.

  2013cited by this paper
• Impaired Phosphorylation and Ubiquitination by p70 S6 Kinase (p70S6K) and Smad Ubiquitination Regulatory Factor 1 (Smurf1) Promote Tribbles Homolog 2 (TRIB2) Stability and Carcinogenic Property in Liver Cancer*

  2013cited by this paper
• The dynamic determinants of reaction specificity in the IMPDH/GMPR family of (β/α)8 barrel enzymes

  2012cited by this paper
• PTBP1‐dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis

  2012cited by this paper
• Deubiquitinases in cancer: new functions and therapeutic options

  2012cited by this paper
• Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications

  2010cited by this paper
• Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

  2010cited by this paper
• Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

  2007cited by this paper
• Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway

  2005cited by this paper
• Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells

  2005cited by this paper
• Inosine 5'-monophosphate dehydrogenase binds nucleic acids in vitro and in vivo.

  2004cited by this paper
• Hepatocellular carcinoma

  1998cited by this paper
• Selective up-regulation of type II inosine 5'-monophosphate dehydrogenase messenger RNA expression in human leukemias.

  1991cited by this paper
• Hepatocellular carcinoma.

  1986cited by this paper

• USP5 inhibition stimulates immunogenic ferroptosis that enhances immunotherapy in diffuse large B-cell lymphoma

  2026cites this paper
• Deubiquitinase USP5 regulates cancer progression and radiosensitivity by stabilizing HOXA10 in non-small cell lung cancer.

  2025cites this paper
• Stabilization of FASN by USP5-mediated deubiquitination promotes hepatocellular carcinoma progression

  2025cites this paper
• LC3-dependent intercellular transfer of phosphorylated STAT1/2 elicits CXCL9+ macrophages and enhances radiation-induced antitumor immunity

  2025cites this paper